The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

Colon cancer is the second leading cause of cancer death among men and women combined in the United States. With early detection, colon cancer is preventable, treatable, and beatable. If you are 50 or older, schedule your screening today by visiting riversideonline.com/colonscreening. | Riverside | Facebook